RT Journal Article
SR Electronic
T1 Immune Modulation Therapy and Imaging: Workshop Report
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 410
OP 417
DO 10.2967/jnumed.117.195610
VO 59
IS 3
A1 Anthony F. Shields
A1 Paula M. Jacobs
A1 Mario Sznol
A1 Michael M. Graham
A1 Ron N. Germain
A1 Lawrence G. Lum
A1 Elizabeth M. Jaffee
A1 Elisabeth G.E. de Vries
A1 Sridhar Nimmagadda
A1 Annick D. Van den Abbeele
A1 David K. Leung
A1 Anna M. Wu
A1 Elad Sharon
A1 Lalitha K. Shankar
YR 2018
UL http://jnm.snmjournals.org/content/59/3/410.abstract
AB A workshop at the National Cancer Institute on May 2, 2016, considered the current state of imaging in assessment of immunotherapy. Immunotherapy has shown some remarkable and prolonged responses in the treatment of tumors. However, responses are variable and frequently delayed, complicating the evaluation of new immunotherapy agents and customizing treatment for individual patients. Early anatomic imaging may show that a tumor has increased in size, but this could represent pseudoprogression. On the basis of imaging, clinicians must decide if they should stop, pause, or continue treatment. Other imaging technologies and approaches are being developed to improve the measurement of response in patients receiving immunotherapy. Imaging methods that are being evaluated include radiomic methods using CT, MRI, and 18F-FDG PET, as well as new radiolabeled small molecules, antibodies, and antibody fragments to image the tumor microenvironment, immune status, and changes over the course of therapy. Current studies of immunotherapy can take advantage of these available imaging options to explore and validate their use. Collection of CT, PET, and MR images along with outcomes from trials is critical to develop improved methods of assessment.